Identification |
Name: | Indomethacin |
Synonyms: | indomethacin methanol solution; indomethacin crystalline; indomethacin usp; indometacin; 1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-ylacetic acid |
CAS: | 53-86-1 |
EINECS: | 200-186-5 |
Molecular Formula: | C19H16ClNO4 |
Molecular Weight: | 357.79 |
InChI: | InChI=1/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) |
Molecular Structure: |
|
Properties |
Transport: | UN 2811 |
Density: | 1.32g/cm3 |
Stability: | Stable. Incompatible with strong oxidizing agents. |
Water Solubility: | Insoluble |
Solubility: | Insoluble |
Appearance: | White crystalline powder |
Specification: |
?Synonyms of Indomethacin (CAS NO.53-86-1) are (1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetic acid ; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure ; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure [German] ; 1-(p-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid ; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid ; 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico ; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- ; Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- .
|
Report: |
Reported in EPA TSCA Inventory.
|
Packinggroup: | I |
Biological Activity: | Cyclooxgenase (COX) inhibitor; displays selectivity for COX-1 (IC 50 values are 230 and 630 nM for human COX-1 and COX-2 respectively). Widely used anti-inflammatory agent. |
Storage Temperature: | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. |
Color: | PALE-YELLOW TO YELLOW-TAN, CRYSTALLINE POWDER CRYSTALS EXHIBIT POLYMORPHISM |
Usage: | Inhibits cyclooxygenase (IC50=0.1uM) selectively over liposygenases (IC50=100uM for 5-,12- and 15-LO). A clinically useful NAISD |
Safety Data |
Hazard Symbols |
T+:Verytoxic
|
|
|